{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14","upperLimit":"21","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Time to neutrophil engraftment is defined from date of infusion to date of neutrophil engraftment. Neutrophil engraftment is defined as ANC \\> 500/mm3 on two consecutive measurements. The date of engraftment is the date of the first ANC \\> 500/mm3.","dispersionType":"95% Confidence Interval","groups":[{"description":"Preparative Regimen: Patients underwent photopheresis on two consecutive days and received pentostatin 4 mg/m2/d (total dose = 8 mg/m2) by continuous IV infusion on two consecutive days following photopheresis. Total body irradiation was administered on two consecutive days following pentostatin for a total of 600 cGy given in three 200 cGy fractionated doses.\n\nTransplantation: Unmanipulated allogeneic bone marrow or G-CSF mobilized peripheral blood stem cells were infused on day 0 within 48 hours of completion of TBI. Minimum cell dose was 2 ×106 CD34 cells/kg recipient.\n\nAcute graft-vs-host-disease (GVHD) prophylaxis: Patients received Cyclosporine or Tacrolimus per institutional preference or protocol beginning no later than day -1. Methotrexate (MTX) was administered on day +1 and +3. Mycofenolate mofetil (MMF) was introduced on day 100 and could be tapered and discontinued after 12 months if no active cGVHD.\n\nCyclosporine: Immunosuppressant\n\nMethotrexate: Antimetabolite","id":"OG000","title":"Arm I"}],"paramType":"MEDIAN","populationDescription":"eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Daily while hospitalized and then at least 1x/week for the first 50 days and then at least every other week until day 100.","title":"Time to Engraftment for Neutrophil","type":"SECONDARY","unitOfMeasure":"days"}